TIDMACPH
Cambridge, UK and Indianapolis, US -- 2 September 2021: Acacia
Pharma Group plc ("Acacia Pharma", the "Group" or the "Company")
(EURONEXT: ACPH), is pleased to announce that it will be hosting a
webinar at 18:00hrs CEST / 12:00pm EDT on Thursday 30 September
2021 entitled "Hospital User Experience with Barhemsys(R) and
Byfavo(R)."
The webinar will feature presentations by Key Opinion Leaders
(KOLs) Tong Joo (TJ) Gan, MD, MBA, MHS, FRCA (UK), FRCA (Ire),
LicAc (Stony Brook University Renaissance School of Medicine) and
Richard P. Dutton, MD, MBA (USAP) who will discuss their experience
using Barhemsys(R) and Byfavo(R) in the hospital setting and the
patient benefit and value they add to invasive medical procedures
for treating post-operative nausea and vomiting (PONV) as well as
providing short-term sedation.
Barhemsys is an intravenous formulation of amisulpride, a
selective dopamine antagonist. It is approved in the U.S. for
treatment and prophylaxis of PONV, alone and in combination with
antiemetics of another class. Byfavo(R) (remimazolam) for injection
is a sedative offering rapid onset/offset for use during invasive
medical procedures lasting 30 minutes or less and has a rapid onset
of sedation and quick post-procedure recovery.
A live Q&A session will follow the presentations and
participants can submit questions during the session via
questions@lifesciadvisors.com
https://www.globenewswire.com/Tracker?data=bFDxGit3mCGOdWbSsA-CqmQC7npnmrpASuzeFTBvO64xQl8HeoE8PAxIjhhUoaJitjQ6JWDmeaozcaem-UqR7V-0OZ08aZACsWmZOO4ryPY4bgGLswVdYQdmcjageHYf
.
Interested parties are requested to register in advance for the
webcast by clicking here
https://www.globenewswire.com/Tracker?data=dKQCRriRBQ837_VVgaIANMqyGgwrGO3EZLYUjWySWmwpe015pdaef_svA7CmoYQ3D_pLlenCcu4L8lSiJjjOjk0NBkuAQ3zBaxqOB7BVQCb21q4w47PqwJQInMN2mZAN0_iKoDsHV4g2Sds5sOu0pDTDvgcK6wcM_Fk7OIZTVO3YwTxOYXhoy4ALw5V3IObnwGcGwr2LhZJM-3d1QjTasg==
. For those who are unable to listen at this time, a replay of the
call will be available on the Company's website and by clicking
here
https://www.globenewswire.com/Tracker?data=dKQCRriRBQ837_VVgaIANBcAgl_IPGsSXJpVorYHJon6_YIRj9xARWCLHSJJWmiqZ92LLuPuE5th81IuXuA7BDaerFZ9QqIVTptXDJIenFhjmiFGsc_JHdOEZCvo7e2DhIz1woMmGkY5rTkH-PO-5k7YIOSaLZpMfd6pij99PML4JThlWTfban5PblZFvvuGf4rhhlhgiyGh21lWEPx9RA==
.
KOL Biographies
Tong Joo (TJ) Gan, MD, MBA, MHS, FRCA (UK), FRCA (Ire), LicAc is Professor and Chairman of the Department of Anesthesiology at Stony Brook University Renaissance School of Medicine in Stony Brook, New York. Previously, Dr. Gan was Professor of Anesthesiology and Vice Chairman for Clinical Research and Faculty Development at Duke University. Dr. Gan received his medical training at the London Hospital Medical College of the University of London.
Dr. Gan is the Founding President of the American Society for
Enhanced Recovery (ASER), President of the Perioperative Quality
Initiative (POQI), a Past President of the Society for Ambulatory
Anesthesia (SAMBA) and the International Society for Anesthetic
Pharmacology (ISAP).
Richard P. Dutton, MD, MBA is Chief Quality Officer for USAP. In
this role, Dr. Dutton leads the committee responsible for data
analysis and performance measurement using the collective data and
evaluations of all U.S. Anesthesia Partners practices to improve
patient safety and clinical outcomes.
Dr. Dutton is a widely recognized leader in anesthesia quality
management. Since 2009, he has served in clinical leadership
positions with the American Society of Anesthesiologists (ASA),
including Chief Quality Officer and Medical Director of the
Anesthesia Quality Institute (AQI). Prior to USAP, he served as
Chief Quality Officer for ASA and as the founding Executive
Director of AQI. The AQI maintains the largest anesthesia registry
in the country. Aggregated data in the registries is used to create
educational materials, quality management benchmarking, academic
papers, comparative effectiveness research and reports for ASA
officers and committees to use to improve the quality of patient
care.
Dr. Dutton completed his undergrad at Harvard University; his
medical training at Tufts University School of Medicine and earned
an MBA from the University of Maryland. He completed his residency
in anesthesiology at Massachusetts General Hospital in Boston and
served as an attending anesthesiologist at the National Naval
Medical Center while on active duty in the United States Navy. In
1994, Dr. Dutton joined the Faculty at the R Adams Cowley Shock
Trauma Center of the University of Maryland, where he served as
Director of Trauma Anesthesiology and Director of Clinical
Operations. Dr. Dutton was promoted to the rank of Professor in
2009, based on his work in trauma system design. He continues to
serve on numerous ASA and federal committees working to develop
measurements for anesthesia performance, perioperative patient
experience and new models of healthcare
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 MEDiSTRAVA Consulting
IR@acaciapharma.com +44 20 7638 9571
acaciapharma@medistrava.com
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on
the development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures, or cancer chemotherapy.
The Company has identified important and commercially attractive
unmet needs in these areas that its product portfolio aims to
address.
Acacia Pharma's first product, Barhemsys(R) (amisulpride
injection) is available in the US for the management of
postoperative nausea & vomiting (PONV).
Byfavo(R) (remimazolam) for injection, a very rapid onset/offset
IV benzodiazepine sedative is approved and launched in the US for
use during invasive medical procedures in adults lasting 30 minutes
or less, such as colonoscopy and bronchoscopy. Byfavo is
in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV)
has successfully completed one proof-of-concept and one Phase 2
dose-ranging study in patients receiving highly emetogenic
chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and
its R&D operations are centred in Cambridge, UK. The Company is
listed on the Euronext Brussels exchange under the ISIN code
GB00BYWF9Y76 and ticker symbol ACPH.
www.acaciapharma.com
Forward looking statements
This announcement includes forward-looking statements, which are
based on current expectations and projections about future events.
These statements may include, without limitation, any statements
preceded by, followed by or including words such as "believe",
"expect", "intend", "may", "plan", "will", "should", "could" and
other words and terms of similar meaning or the negative thereof.
Forward-looking statements may and often do differ materially from
actual results. These forward-looking statements are subject to
risks, uncertainties and assumptions about the Company and its
subsidiaries and investments, including, among other things, the
development of its business, trends in its operating industry, and
future capital expenditures and acquisitions. By their nature,
forward-looking statements involve risk and uncertainty because
they relate to future events and circumstances. Any forward-looking
statements reflect the Company's current view with respect to
future events and are subject to risks relating to future events
and other risks, uncertainties and assumptions relating to the
Group's business, results of operations, financial position,
prospects, growth or strategies and the industry in which it
operates. Save as required by law or applicable regulation, the
Company and its affiliates expressly disclaim any obligation or
undertaking to update, review or revise any forward-looking
statement contained in this announcement whether as a result of new
information, future developments or otherwise. Forward-looking
statements speak only as of the date they are made.
(END) Dow Jones Newswires
September 02, 2021 01:00 ET (05:00 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2023 to Mar 2024